Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
PureTech Health ( (GB:PRTC) ) has shared an update.
PureTech Health announced that all resolutions at its Annual General Meeting were passed, though resolutions on directors’ remuneration and the re-election of Ms. Kiran Mazumdar-Shaw received less than 80% approval. The company emphasizes its commitment to engaging with shareholders on remuneration and governance issues, promising an update within six months in line with the UK Corporate Governance Code 2024.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall stock score reflects strong earnings call insights and promising valuation metrics. While its financial performance shows some liquidity strength, operational risks and inconsistent profitability are concerns. Technical indicators suggest potential short-term positivity.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to treat devastating diseases. The company has a robust portfolio of 29 therapeutics and therapeutic candidates, including three FDA-approved treatments, developed through its research and development team and network of scientists and clinicians.
Average Trading Volume: 646,662
Technical Sentiment Signal: Sell
Current Market Cap: £338.7M
For a thorough assessment of PRTC stock, go to TipRanks’ Stock Analysis page.